EVELIQURE BIOTECHNOLOGIES GMBH
EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one of the two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains.
EVELIQURE BIOTECHNOLOGIES GMBH
Social Links:
Industry:
Life Science
Founded:
2012-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.eveliqure.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
SpyBiotech
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.
Current Employees Featured
Founder
Investors List
Arax Capital Partners
Arax Capital Partners investment in Series A - EveliQure Biotechnologies GmbH
Kinled Holding
Kinled Holding investment in Venture Round - EveliQure Biotechnologies GmbH
Official Site Inspections
http://www.eveliqure.com Semrush global rank: 6.17 M Semrush visits lastest month: 1.31 K
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "EveliQure Biotechnologies GmbH"
Biotech Company | Eveliqure Biotechnologies | Austria
In addition, Eveliqure has introduced the expression of non-shigella derived antigens into the strain to achieve protection against multiple pathogens. … See details»
EveliQure Biotechnologies GmbH - Crunchbase
EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against … See details»
EveliQure Biotechnologies GmbH - Drug pipelines, Patents, Clinical ...
May 7, 2025 Explore EveliQure Biotechnologies GmbH with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, and 6 literature, Technology Platform:Therapeutic vaccine, … See details»
Eveliqure Biotechnologies GmbH | Devex
Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- … See details»
Eveliqure - Shigetecvax
Eveliqure Biotechnologies is an Austrian biotech company that is the game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is … See details»
Life Sciences Directory: EveliQure Biotechnologies GmbH
Organization type RDM biotech/pharma Region Vienna Cluster LISAvienna Focus human health Profile. Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines … See details»
Eveliqure - Vienna BioCenter
Eveliqure Biotechnologies is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the … See details»
Board | Eveliqure Biotechnologies | Austria
Founder and CEO CEBINA GmbH, Co-founder and CEO Calyxha Biotechnologies GmbH, Co-Founder and CEO/CSO Algonist Biotechnologies, Former Co-founder and CSO, Arsanis Inc. … See details»
Eveliqure Biotechnologies - Alumni - University at Buffalo
About Eveliqure Biotechnologies Eveliqure is a game-changer vaccine company, championing novel technologies to make the world safe from diarrhoeal diseases caused by Shigella and ETEC … See details»
EveliQure Biotechnologies GmbH (EveliQure Biotechnologies GmbH) …
May 7, 2025 了解EveliQure Biotechnologies GmbH (EveliQure Biotechnologies GmbH)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验和6篇文献，技术平台:治疗性疫苗，药 … See details»
EveliQure Biotechnologies GmbH - Contacts, Employees, Board …
EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. … See details»
Eveliqure announces the award of a NIAID contract to finance Phase …
VIENNA, Sept. 9, 2020 /PRNewswire/ -- Eveliqure Biotechnologies GmbH today announces the award of a US government contract from the National Institute of Allergy and Infectious Diseases … See details»
Vision & Mission | Eveliqure Biotechnologies | Austria
Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea.Eveliqure is passionate about improving the quality of life for both … See details»
EveliQure Biotechnologies GmbH - Funding, Financials ... - Crunchbase
EveliQure Biotechnologies GmbH has raised a total of . obfuscated. obfuscated. in funding over 2 rounds. Their latest funding was raised on Jul 1, 2019 from a Series A round. Which funding … See details»
News | Eveliqure Biotechnologies | Austria
2019 Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries is supported by the Wellcome Trust | Download . 25. 10. 2019 The … See details»
Eveliqure's effort to develop a Shigella-ETEC combination ... - BioSpace
Eveliqure’s vaccine, ShigETEC, is the only vaccine close to clinical testing that targets the two major bacterial pathogens causing diarrhea in travelers and military personnel to endemic countries and … See details»
Technology | Eveliqure Biotechnologies | Austria
Live attenuated Shigella strains developed so far are invasive and afford serotype-dependent protection. In contrast, the proprietary Eveliqure vaccine technology platform is based on a live, … See details»
Our solution | Eveliqure Biotechnologies | Austria
The Eveliqure platform is amenable for the heterologous expression of diarrheal antigens and therefore can provide protective immunity against multiple pathogens. Eveliqure’s first product, … See details»
EveliQure's diarrhoea vaccine to advance towards clinical trials ...
EveliQure Biotechnologies announces the award of a grant from Horizon2020 - the European Union´s Research and Innovation programme - that supports first-in-man studies of its proprietary … See details»
How it works | Eveliqure Biotechnologies | Austria
The proprietary Eveliqure vaccine technology platform is based on a live attenuated Shigella vaccine strain able to induce broad protection against shigellosis due to targeted genetic mutations These … See details»